Interleukin-30 promotes breast cancer growth and progression

Irma Airoldi, Claudia Cocco, Carlo Sorrentino, Domenico Angelucci, Serena Di Meo, Lamberto Manzoli, Silvia Esposito, Domenico Ribatti, Maria Bertolotto, Laura Iezzi, Clara Natoli, Emma Di Carlo

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The inflammatory tissue microenvironment that promotes the development of breast cancer is not fully understood. Here we report a role for elevated IL30 in supporting the breast cancer cell viability and invasive migration. IL30 was absent in normal mammary ducts, ductules, and acini of histologically normal breast and scanty in the few stromal infiltrating leukocytes. In contrast, IL30 was expressed frequently in breast cancer specimens where it was associated with triple-negative and HER2+ molecular subtypes. In stromal leukocytes found in primary tumors or tumor-draining lymph nodes, which included mainly CD14+ monocytes, CD68+ macrophages, and CD33+/CD11b+ myeloid cells, IL30 levels increased with disease stage and correlated with recurrence. A negative correlation was determined between IL30 expression by nodal stromal leukocytes and overall survival. In vitro studies showed that human recombinant IL30 upregulated expression of a prooncogenic program, including especially IL6 in both triplenegative and HER2+ breast cancer cells. In triple-negative breast cancer cells, IL30 boosted a broader program of proliferation, invasive migration, and an inflammatory milieu associated with KISS1-dependent metastasis. Silencing of STAT1/STAT3 signaling hindered the regulation of the primary growth and progression factors in breast cancer cells. IL30 administration in vivo fostered the growth of triple-negative breast cancer by promoting proliferation and vascular dissemination of cancer cells and the accumulation of intratumoral CD11b+/Gr1+ myeloid cell infiltrates. Overall, our results show how IL30 regulates breast cancer cell viability, migration, and gene expression to promote breast cancer growth and progression and its impact on patient outcome.

Original languageEnglish
Pages (from-to)6218-6229
Number of pages12
JournalCancer Research
Volume76
Issue number21
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Interleukins
Breast Neoplasms
Growth
Triple Negative Breast Neoplasms
Leukocytes
Myeloid Cells
Cell Survival
Breast
Neoplasms
Cell Movement
Blood Vessels
Monocytes
Interleukin-6
Intercellular Signaling Peptides and Proteins
Lymph Nodes
Macrophages
Neoplasm Metastasis
Gene Expression
Recurrence
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Airoldi, I., Cocco, C., Sorrentino, C., Angelucci, D., Di Meo, S., Manzoli, L., ... Di Carlo, E. (2016). Interleukin-30 promotes breast cancer growth and progression. Cancer Research, 76(21), 6218-6229. https://doi.org/10.1158/0008-5472.CAN-16-0189

Interleukin-30 promotes breast cancer growth and progression. / Airoldi, Irma; Cocco, Claudia; Sorrentino, Carlo; Angelucci, Domenico; Di Meo, Serena; Manzoli, Lamberto; Esposito, Silvia; Ribatti, Domenico; Bertolotto, Maria; Iezzi, Laura; Natoli, Clara; Di Carlo, Emma.

In: Cancer Research, Vol. 76, No. 21, 01.11.2016, p. 6218-6229.

Research output: Contribution to journalArticle

Airoldi, I, Cocco, C, Sorrentino, C, Angelucci, D, Di Meo, S, Manzoli, L, Esposito, S, Ribatti, D, Bertolotto, M, Iezzi, L, Natoli, C & Di Carlo, E 2016, 'Interleukin-30 promotes breast cancer growth and progression', Cancer Research, vol. 76, no. 21, pp. 6218-6229. https://doi.org/10.1158/0008-5472.CAN-16-0189
Airoldi I, Cocco C, Sorrentino C, Angelucci D, Di Meo S, Manzoli L et al. Interleukin-30 promotes breast cancer growth and progression. Cancer Research. 2016 Nov 1;76(21):6218-6229. https://doi.org/10.1158/0008-5472.CAN-16-0189
Airoldi, Irma ; Cocco, Claudia ; Sorrentino, Carlo ; Angelucci, Domenico ; Di Meo, Serena ; Manzoli, Lamberto ; Esposito, Silvia ; Ribatti, Domenico ; Bertolotto, Maria ; Iezzi, Laura ; Natoli, Clara ; Di Carlo, Emma. / Interleukin-30 promotes breast cancer growth and progression. In: Cancer Research. 2016 ; Vol. 76, No. 21. pp. 6218-6229.
@article{e178d179d0e945e889edb7447987021b,
title = "Interleukin-30 promotes breast cancer growth and progression",
abstract = "The inflammatory tissue microenvironment that promotes the development of breast cancer is not fully understood. Here we report a role for elevated IL30 in supporting the breast cancer cell viability and invasive migration. IL30 was absent in normal mammary ducts, ductules, and acini of histologically normal breast and scanty in the few stromal infiltrating leukocytes. In contrast, IL30 was expressed frequently in breast cancer specimens where it was associated with triple-negative and HER2+ molecular subtypes. In stromal leukocytes found in primary tumors or tumor-draining lymph nodes, which included mainly CD14+ monocytes, CD68+ macrophages, and CD33+/CD11b+ myeloid cells, IL30 levels increased with disease stage and correlated with recurrence. A negative correlation was determined between IL30 expression by nodal stromal leukocytes and overall survival. In vitro studies showed that human recombinant IL30 upregulated expression of a prooncogenic program, including especially IL6 in both triplenegative and HER2+ breast cancer cells. In triple-negative breast cancer cells, IL30 boosted a broader program of proliferation, invasive migration, and an inflammatory milieu associated with KISS1-dependent metastasis. Silencing of STAT1/STAT3 signaling hindered the regulation of the primary growth and progression factors in breast cancer cells. IL30 administration in vivo fostered the growth of triple-negative breast cancer by promoting proliferation and vascular dissemination of cancer cells and the accumulation of intratumoral CD11b+/Gr1+ myeloid cell infiltrates. Overall, our results show how IL30 regulates breast cancer cell viability, migration, and gene expression to promote breast cancer growth and progression and its impact on patient outcome.",
author = "Irma Airoldi and Claudia Cocco and Carlo Sorrentino and Domenico Angelucci and {Di Meo}, Serena and Lamberto Manzoli and Silvia Esposito and Domenico Ribatti and Maria Bertolotto and Laura Iezzi and Clara Natoli and {Di Carlo}, Emma",
year = "2016",
month = "11",
day = "1",
doi = "10.1158/0008-5472.CAN-16-0189",
language = "English",
volume = "76",
pages = "6218--6229",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Interleukin-30 promotes breast cancer growth and progression

AU - Airoldi, Irma

AU - Cocco, Claudia

AU - Sorrentino, Carlo

AU - Angelucci, Domenico

AU - Di Meo, Serena

AU - Manzoli, Lamberto

AU - Esposito, Silvia

AU - Ribatti, Domenico

AU - Bertolotto, Maria

AU - Iezzi, Laura

AU - Natoli, Clara

AU - Di Carlo, Emma

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The inflammatory tissue microenvironment that promotes the development of breast cancer is not fully understood. Here we report a role for elevated IL30 in supporting the breast cancer cell viability and invasive migration. IL30 was absent in normal mammary ducts, ductules, and acini of histologically normal breast and scanty in the few stromal infiltrating leukocytes. In contrast, IL30 was expressed frequently in breast cancer specimens where it was associated with triple-negative and HER2+ molecular subtypes. In stromal leukocytes found in primary tumors or tumor-draining lymph nodes, which included mainly CD14+ monocytes, CD68+ macrophages, and CD33+/CD11b+ myeloid cells, IL30 levels increased with disease stage and correlated with recurrence. A negative correlation was determined between IL30 expression by nodal stromal leukocytes and overall survival. In vitro studies showed that human recombinant IL30 upregulated expression of a prooncogenic program, including especially IL6 in both triplenegative and HER2+ breast cancer cells. In triple-negative breast cancer cells, IL30 boosted a broader program of proliferation, invasive migration, and an inflammatory milieu associated with KISS1-dependent metastasis. Silencing of STAT1/STAT3 signaling hindered the regulation of the primary growth and progression factors in breast cancer cells. IL30 administration in vivo fostered the growth of triple-negative breast cancer by promoting proliferation and vascular dissemination of cancer cells and the accumulation of intratumoral CD11b+/Gr1+ myeloid cell infiltrates. Overall, our results show how IL30 regulates breast cancer cell viability, migration, and gene expression to promote breast cancer growth and progression and its impact on patient outcome.

AB - The inflammatory tissue microenvironment that promotes the development of breast cancer is not fully understood. Here we report a role for elevated IL30 in supporting the breast cancer cell viability and invasive migration. IL30 was absent in normal mammary ducts, ductules, and acini of histologically normal breast and scanty in the few stromal infiltrating leukocytes. In contrast, IL30 was expressed frequently in breast cancer specimens where it was associated with triple-negative and HER2+ molecular subtypes. In stromal leukocytes found in primary tumors or tumor-draining lymph nodes, which included mainly CD14+ monocytes, CD68+ macrophages, and CD33+/CD11b+ myeloid cells, IL30 levels increased with disease stage and correlated with recurrence. A negative correlation was determined between IL30 expression by nodal stromal leukocytes and overall survival. In vitro studies showed that human recombinant IL30 upregulated expression of a prooncogenic program, including especially IL6 in both triplenegative and HER2+ breast cancer cells. In triple-negative breast cancer cells, IL30 boosted a broader program of proliferation, invasive migration, and an inflammatory milieu associated with KISS1-dependent metastasis. Silencing of STAT1/STAT3 signaling hindered the regulation of the primary growth and progression factors in breast cancer cells. IL30 administration in vivo fostered the growth of triple-negative breast cancer by promoting proliferation and vascular dissemination of cancer cells and the accumulation of intratumoral CD11b+/Gr1+ myeloid cell infiltrates. Overall, our results show how IL30 regulates breast cancer cell viability, migration, and gene expression to promote breast cancer growth and progression and its impact on patient outcome.

UR - http://www.scopus.com/inward/record.url?scp=84995676866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995676866&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-0189

DO - 10.1158/0008-5472.CAN-16-0189

M3 - Article

VL - 76

SP - 6218

EP - 6229

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 21

ER -